跳至主要内容
临床试验/ACTRN12618001794291
ACTRN12618001794291尚未招募2 期

Pilot Randomised Controlled Trial of Prophylactic Pregabalin for Pain in Radical Head and Neck Cancer Patients Receiving Radiotherapy

South Eastern Sydney Local Health District0 个研究点目标入组 30 人开始时间: 2018年11月2日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Gender: male and female
  • Age: >18 years
  • Patients receiving curative radiotherapy to the head and neck area to treat mucosal squamous cell carcinomas (SCC), with or without chemotherapy/cetuximab
  • Both P16 positive and negative SCC (a known variant in histology)
  • Patients undergoing radiotherapy (RT) as both adjuvant and radical treatment
  • Willingness to give written informed consent

排除标准

  • Patients receiving palliative radiotherapy to the head and neck.
  • Patients in whom pregabalin is contraindicated E.g.
  • ointolerance or allergy to pregabalin/gabapentin
  • opatients on buprenorphine or propoxyphene
  • Patients on neuroleptic medication or other neuropathic agents for other medical conditions
  • Inability to provide informed consent
  • Inability to complete the visual aspects of the questionnaires without assistance (other then explanation)
  • Patients with moderate/severe renal impairment with GFR (glomerular filtration rate) of <50ml/min as calculated according to Cockroft-Gault formula using screening blood test
  • Platelet count <100
  • Absolute neutrophil count <1.5x109/L
  • Alanine aminotransferase (ALT) >2.5x upper limit of normal
  • Patients who are pregnant or lactating
  • Previous suicidal ideation

研究者

相似试验